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Abstract
Continuous-flow left ventricle assist devices (CF-LVADs) has become an essential modality in the management of
stage D heart failure (HF) with significant improvement in survival and quality of life. Due to the durability of such
devices and long term support complications such as bleeding and aortic insufficiency has emerged. Bleeding
accounts for more than 20 % with the majority being from the gastrointestinal tract. The increase of bleeding
tendency are mainly attributed to the loss of large von Willebrand’s Factor (vWF) multimers due to shear stress with
the chronic intake of anticoagulants. We are reporting two cases of patients with Stage D HF and history of
hemorrhoids presenting for LVAD implantation. Many efforts that decrease bleeding related to CF-LVADs will be
discussed with focus on hemorrhoids.
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Background
Continuous-flow left ventricle assist devices (CF-LVADs)
has become an essential modality in the management of
stage D heart failure (HF) with significant improvement
in survival and quality of life. Compared with the older
pulsatile devices, CF-LVADs has less complications,
mainly infections and thrombosis [1–4], due to the dur-
ability of such devices and long term support. Other
complications are emerging such as bleeding and aortic
insufficiency. Bleeding is one of the major reported com-
plications accounting for more than 20 % [4], with the
majority being from the gastrointestinal tract [2], espe-
cially with the need of long-term anticoagulation ther-
apy. The increase of bleeding tendency are mainly
attributed to the loss of large von Willebrand’s Factor
(vWF) multimers due to shear stress [4]. Many efforts
are being implemented to decrease bleeding related to
CF-LVADs [4].
We are reporting two cases of patients with Stage D
HF and history of hemorrhoids presenting for LVAD
implantation.
Case 1
Fifty-five-year-old male with valvular cardiomyopathy re-
ferred to our institution with stage D HF and multi-organ
failure. He was in INTERMACS profile I, in cardiogenic
shock, on Intra-aortic balloon pump (IABP) and intra
venous inotropes and pressors. He also suffered acute
on top of chronic renal failure for which hemodialysis
was initiated. His hospital mortality HeartMate II risk
score reached 73 %.
Two weeks after decongestion with ultrafiltration, near
optimization of nutritional status and normalization of
pro-thrombin time, a HeartMate II LVAD was implanted
as a bridge to decision.
One week post LVAD implantation, he developed se-
vere lower gastrointestinal (GI) bleeding attributed to
stage III hemorrhoids, which resulted in a hypovolemic
shock necessitating multiple transfusions and withhold-
ing anticoagulation. In addition to lower GI bleeding, he
was still supported by mechanical ventilation and
hemodialysis. Due to profuse bleeding and necessity
for long term anticoagulation, he underwent urgent
hemorrhoidal artery ligation (HAL). Post surgery he
developed hypotension with elevated pump flow, low
pulse index and elevated pump power, suggestive of
pump thrombosis. This led to further vascular collapse
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and right ventricular failure resulting in cardiopulmo-
nary arrest with unsuccessful resuscitation.
Case 2
Fifty-five-year-old male with dilated cardiomyopathy on
optimal medical therapy and post CRT –D implantation,
admitted with acute decompensated heart failure. He
was in cardiogenic shock and stabilized thereafter with
intravenous inotropes. He was inotrope-dependent (HF
Stage D INTERMACS profile 3) and a candidate for a
life saving CF-LVAD implantation. During preparation
for the procedure he developed episodes of hematoche-
zia. Workup showed bleeding from grade 3 internal
hemorrhoids. HAL was performed prior to LVAD sur-
gery. LVAD implantation was performed uneventfully.
Hematochezia did not recur despite therapeutic anticoa-
gulation. During a 2 year-follow up, the patient reported
no GI bleeding.
Discussion
As more than 5 million people have congestive heart fail-
ure and with the number projected to increase [5], LVAD
became the standard of care for patients with heart failure
refractory to optimal medical treatment and requiring cir-
culatory support as a bridge to transplant, destination
therapy or bridge to myocardial recovery [6].
In order to avoid device related thromboembolic events,
it is recommended that patients with LVAD be maintained
on antiplatelet, and therapeutic anticoagulation [7]. In
addition LVAD patients are at increased risk of bleeding
due to angiodysplasia and acquired vonWilleberand’s dis-
ease especially in continuous flow LVAD (CF-LVAD) [8].
In multiple reports angiodysplasia was found as the culprit
lesion for GI bleeding. In continuous-flow LVADs, blood
is directed out of the left ventricle directly into the aorta
without passing through the aortic valve which results in
less frequent opening of the valve causing a reduced aortic
pulse pressure. This causes a reduction in the arteriole
smooth muscle causing a dilation in mucosal veins and
angiodysplasia formation [9]. Also Efficient platelet aggre-
gation and adhesion depends on the high molecular
weight (HMW) multimers of vWF. Similarly to aortic
stenosis, high shear stress due to the passage of blood
through continuous flow LVAD and biventricular pulsatile
VAD results in the cleavage of HMW multimers, resulting
in dysfunction vWF and acquired von Willerbrand’s
disease [8–11]. Therefore bleeding events for these pa-
tients increase.
The incidence of upper and lower GI bleeding in both
pulsatile and non pulsatile LVAD patients increased,
despite the advances in the hemodynamics and bio-
compatibility of these devices, more notable in the
non pulsatile group [5, 12].In a report by Harvey et al.
the incidence of GI bleeding after LVAD implantation
varied between 18–40 % [6]. Although in many reports
it is unknown, the bleeding site can involve the entire
gastrointestinal tract [13], with upper being more com-
mon than lower GI bleeding, mainly in the stomach,
followed by duodenum, jejunum and esophagus [9]. In-
ternal hemorrhoids, as a source of lower GI bleed is
common, as reported in a case series by Siddiqui et al.,
to be the source of bleeding in 8 out of 38 cases [5].
With the increased incidence of GI bleeding following
LVAD surgery, preventing this complication prior to
embarking on implant might be reasonable, especially in
patients at higher risk of bleeding.
In Case 1, patient had HAL post LVAD implant, yet
this was complicated by cardiac arrest and death despite
many efforts to resuscitate the patient. That being said,
in Case 2 we opted for hemorrhoidal artery ligation
(HAL) before LVAD implantation, despite the patient’s
clinical status. Thus avoided any fatal complications re-
lated to bleeding or a second procedure (e.g. HAL) post
LVAD implant.
HAL is an operation started in 1996 by Morinaga et al.
for the surgical treatment of moderate grade and pro-
lapsed hemorrhoids. It centers around the treatment of
hemorrhoids by cutting off the blood supply with guid-
ance from a Doppler probe [14]. Hence, this procedure
is a low risk, less invasive and efficacious procedure,
making it a good alternative to conventional haemor-
rhoidectomy or stapled haemorrhoidopexy in the short
and medium term as endorsed by the National Institute
for Health and Care (NICE) [15]. According to the 2014
ESC/ESA Guidelines on non-cardiac surgery, heart fail-
ure is a well-recognized factor for peri-operative and
post-operative cardiac events, while patients with left
ventricular ejection fraction (LVEF) <30 % might be at a
greater risk [16]. However since HAL is less invasive
than conventional open hemorrhoidectomy, it was the
procedure of choice in our patient considering the po-
tential for a related GI complication before LVAD im-
plantation. It should be noted, that Jeong et al, in there
one year follow up of patients post dopppler-guided
HAL, noted a recurrence rate including re-bleeding of
14 %. However this large number was higher than previ-
ously published reports [17].
Secondary prevention strategies for GI bleed post
LVAD implantation had been discussed, including treat-
ing Helicobacter pylori, daily proton pump inhibitor use,
limiting non steroidal anti inflammatory use and sub cu-
taneous octreotide injection to treat angiodysplasia [9].
Also lowering pump speed was suggested as an approach
to limit bleeding [18]. Based on the 2013 International
Society for Heart and Lung Transplantation Guidelines
for Mechanical Circulatory Support: “reducing the pump
speed for continuous flow pumps in the setting of
recurrent gastrointestinal bleeding due to arteriovenous
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malformations may be considered”. Considering that
angiodysplasia is caused by reduced pulsatility, thus de-
creasing pump speed can result in increase pulsatility
and decreased angiodysplasia formation [18]. Also re-
peated transfusion of vWF has been reported to control
bleeding caused by angiodysplasia [10], however it is not
recommended yet.
In our view many efforts should be made preopera-
tively to decrease bleeding complications related to
LVAD. Some of these primary prevention measures in-
clude preoperative assessment of the coagulation profile,
vitamin K administration in case of elevated INR levels
with postponement of surgery 5 to 7 days to allow cessa-
tion of vitamin K antagonists and thineopyridines,
screening for Heparin Induced Thrombocytopenia (HIT)
and in some cases the use of recombinant factor VII [4].
Screening for common cause of bleed, such as hemor-
rhoids, prior to surgery as primary prevention had not
been addressed previously. Hemorrhoids are recognized
as a common cause of lower GI bleeding; however its
true epidemiology is unknown. Its estimated prevalence
is 4.4 % in the United States [19]. Being that common as
a cause of GI bleeding, screening for hemorrhoids prior
to LVAD surgery could prevent this complication espe-
cially that approximately 40 % of patients with hemor-
rhoids might be asymptomatic.
Since with the current available evidence, routine
screening for hemorrhoids in asymptomatic patients
might not be cost effective, our two cases raise the need
for a multicenter study to shed light on this patho-
logical entity and its management in the LVAD popula-
tion, as a potential measure to reduce post LVAD
bleeding complications.
Conclusion
GI bleeding is a common complication in LVAD patient
while hemorrhoids are a potential cause of mortality and
morbidity.Since LVAD patients are in continuous need
for therapeutic anticoagulation, screening and managing
hemorrhoids in the advanced stages of HF maybe rec-
ommended to reduce the risk of potential bleeding and
bleeding complications in LVAD patients. Further stud-
ies are required to assess the benefits and cost effective-
ness of the suggested therapeutic intervention.
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